or a salt or solvate or stereoisomer thereof;

wherein:

D is drug moiety;

T is a targeting moiety;

X is a hydrophilic self-immolative linker;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is bond or a spacer**;** and

A is an acyl unit.

[0011] In some examples, provided is a compound of Formula (Ia):



(Ia)

or a salt or solvate or stereoisomer thereof; wherein D, T, X, L^1, L^2, L^3, L^4 and A are as defined for Formula (I), and p is 1 to 20. In some examples, p is 1 to 8. In some examples, p is 1 to 6. In some examples, p is 1 to 4. In some examples, p is 2 to 4. In some examples, p is 1, 2, 3 or 4.

[0012] The present disclosure also provides a compound of Formula (II):



(II)

or a salt or solvate or stereoisomer thereof;

wherein:

D is drug moiety;

T is a targeting moiety;

R^1 is hydrogen, unsubstituted or substituted $C_{1\text{-}3}$ alkyl, or unsubstituted or substituted heterocyclyl;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond, a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is bond or a spacer**;** and

A is an acyl unit.

[0013] In some examples, provided is a compound of Formula (IIa):



(IIa)

or a salt or solvate or stereoisomer thereof; wherein D, T, L^1, L^2, L^3, L^4 and A are as defined for Formula (II), and p is 1 to 20. In some examples, p is 1 to 8. In some examples, p is 1 to 6. In some examples, p is 1 to 4. In some examples, p is 2 to 4. In some examples, p is 1, 2, 3 or 4.

[0013a] In one aspect, the present disclosure refers to a compound of the formula:

(i) formula (II):



(II)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

T is a targeting moiety;

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit;

or

(ii) formula (IIa):



(IIa)

or a salt or solvate or stereoisomer thereof;

wherein:

p is 1 to 20;

D is a drug moiety;

T is a targeting moiety;

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit.

[0013b] In one aspect, the present disclosure refers to a process for making a compound of the formula:

(i) formula (II):



(II)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

T is an antibody;

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit;

comprising reacting an antibody with Compound Z:



(Compound Z),

or a salt or solvate or stereoisomer thereof;

or

(ii) formula (IIa):



(IIa)

or a salt or solvate or stereoisomer thereof;

wherein:

p is 1 to 20;

D is a drug moiety;

T is an antibody;

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit;

comprising reacting an antibody with Compound Z:



(Compound Z),

or a salt or solvate or stereoisomer thereof, optionally wherein the antibody comprises one or more sulfhydryl groups.

[0013c] In one aspect, the present disclosure refers to a compound, or a salt or solvate or stereoisomer thereof, wherein the compound is prepared by a process as disclosed herein, wherein the antibody comprises one or more sulfhydryl groups.

[0014] The present disclosure also provides a compound of Formula (III):



(III),

or a salt or solvate or stereoisomer thereof;

wherein T is a targeting moiety.

[0015] In some examples, provided is a compound of Formula (IIIa):



(IIIa)

or a salt or solvate or stereoisomer thereof; wherein T is a targeting moiety and p is 1 to 20. In some examples, p is 1 to 8. In some examples, p is 1 to 6. In some examples, p is 1 to 4. In some examples, p is 2 to 4. In some examples, p is 1, 2, 3 or 4.

[0016] The present disclosure provides a compound of Formula (IV):



(IV),

or a salt or solvate or stereoisomer thereof;

wherein T is a targeting moiety.

[0017] In some examples, provided is a compound of Formula (IVa):



(IVa)

or a salt or solvate or stereoisomer thereof; wherein T is a targeting moiety and p is 1 to 20. In some examples, p is 1 to 8. In some examples, p is 1 to 6. In some examples, p is 1 to 4. In some examples, p is 2 to 4. In some examples, p is 1, 2, 3 or 4.

[0018] The present disclosure provides a compound of Formula (V):



(V),

or a salt or solvate or stereoisomer thereof;

wherein T is a targeting moiety.

[0019] In some examples, provided is a compound of Formula (Va):



(Va)

or a salt or solvate or stereoisomer thereof; wherein T is a targeting moiety and p is 1 to 20. In some examples, p is 1 to 8. In some examples, p is 1 to 6. In some examples, p is 1 to 4. In some examples, p is 2 to 4. In some examples, p is 1, 2, 3 or 4.

[0020] The present disclosure provides a compound of Formula (VI):



(VI)

or a salt or solvate thereof.

[0021] The present disclosure provides a compound of Formula (VII):



(VII)

or a salt or solvate thereof.

[0022] The present disclosure provides a compound of Formula (VIII):



(VIII)

[0023] The present disclosure provides a compound of Formula (XII):



(XII)

or a salt or solvate or stereoisomer thereof; wherein R is NO_2 or NH_2.

[0023a] In one aspect, the present disclosure refers to a compound which is:

(i) a compound of formula:



(Compound X)

or a salt or solvate or stereoisomer thereof;

wherein:

L^2 is a bond or a second self-immolative linker;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

(ii) a compound of formula:



(Compound Z)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

(iii) a compound of formula:



(Compound X^1)

or a salt or solvate or stereoisomer thereof;

wherein:

L^2 is a bond or a second self-immolative linker;

L^3 is a peptide linker; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

(iv) a compound of formula:



(Compound Y^1)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

or

(v) a compound of Formula (XII)



(XII)

or a salt or solvate or stereoisomer thereof; wherein R is NO_2 or NH_2.

[0023b] In one aspect, the present disclosure refers to a method of preparing a compound which is: (i) Compound X:



(Compound X)

or a salt or solvate or stereoisomer thereof;

wherein:

L^2 is a bond or a second self-immolative linker;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

comprising reacting Compound W: A-L^4-L^3-L^2; and Compound I:  ;

(ii) Compound Z:



(Compound Z)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit

R^1 is hydrogen, unsubstituted or substituted $C_{1\text{-}3}$ alkyl, or unsubstituted or substituted heterocyclyl;

comprising:

reacting Compound X:  and p-nitrophenyl chloroformate

to form Compound Y:  ; and

reacting Compound Y with a compound comprising L^1-D;

(iii) Compound X^1:



(Compound X^1)

or a salt or solvate or stereoisomer thereof;

wherein:

L^2 is a bond or a second self-immolative linker;

L^3 is a peptide linker; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

comprising: reacting Compound W^1: L^3-L^2; and Compound I:  .

(iv) Compound Y^1:



(Compound Y^1)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

comprising: reacting Compound X^1:  ; and a compound comprising L^1-D;

or (v) Compound Z:



(Compound Z)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;**

A is an acyl unit; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

comprising: reacting Compound Y^1:  , and a compound comprising A-L^4.

[0024] In certain examples, the compound of Formulae (I)-(XII) is a compound selected from those species described or exemplified in the detailed description herein.

[0025] In certain examples of the compound of Formulae (I)-(V) or (Ia)-(Va), T is an antibody targeting molecule. In some examples, T is antibody h5F1Ca.1 or c5D7. In further examples, one or more amino acid residues of the heavy chain and/or the light chain of the antibody are

replaced with cysteine residues (*e.g.*, engineered to comprise cysteine residue at a position not present in the parent antibody). In some examples, one or more amino acid residues of the Fc region of the antibody are replaced with a cysteine residue. In some examples, one or more amino acid residues of the Fc region of the antibody are at positions 157, 169 and/or 442 using EU numbering. In some examples of the compound of Formulae (I)-(V) or (Ia)-(Va), D is linked to T by way of the added (e.g. engineered) cysteine residue.

[0026] In a further example, the present disclosure provides a pharmaceutical composition comprising at least one compound of Formulae (I)-(V) or (Ia)-(Va) or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions according to the examples may further comprise a pharmaceutically acceptable excipient. The present disclosure also provides a compound of Formulae (I)-(V) or (Ia)-(Va) or a pharmaceutically acceptable salt thereof for use as a medicament.

[0026a] In one aspect, the present disclosure refers to a pharmaceutical composition comprising the compound as disclosed herein, or a salt or solvate or stereoisomer thereof, and a pharmaceutically acceptable carrier.

[0027] In another example, the present disclosure provides a method of killing a cell, comprising administering to the cell an amount of the compound of Formulae (I)-(V) or (Ia)-(Va) sufficient to kill the cell.

[0027a] In one aspect, the present disclosure refers to a compound as disclosed herein, or a salt or solvate or stereoisomer thereof, for use in a method of killing a cell, the method comprising administering to the cell an amount of said compound sufficient to kill the cell;

wherein optionally the cell is a cancer cell;

and wherein optionally the cancer cell is a gastric cancer cell, pancreatic cancer cell, colorectal cancer cell, lung cancer cell, esophageal cancer cell, gallbladder cancer cell, head and neck cancer cell, liver cancer cell, endometrial carcinoma cell, salivary gland carcinoma cell, lymphoma cell, breast cancer cell, cervical cancer cell, or ovarian cancer cell.

[0028] In another example, the present disclosure provides a method of treating cancer in an individual in need thereof comprising administering to the individual an effective amount of a compound of Formulae (I)-(V) or (Ia)-(Va).

[0028a] In one aspect, the present disclosure refers to a compound as disclosed herein, or a salt or solvate or stereoisomer thereof, for use in the treatment of cancer;

wherein optionally the cancer is gastric cancer, pancreatic cancer, colorectal cancer, lung cancer, esophageal cancer, gallbladder cancer, head and neck cancer, liver cancer, endometrial carcinoma, salivary gland carcinoma, lymphoma, breast cancer, cervical cancer, or ovarian cancer.

[0028b] In one aspect, the present disclosure refers to use of a compound as disclosed herein, or a salt or solvate or stereoisomer thereof, in the manufacture of a medicament for treating cancer; wherein optionally the cancer is gastric cancer, pancreatic cancer, colorectal cancer, lung cancer, esophageal cancer, gallbladder cancer, head and neck cancer, liver cancer, endometrial carcinoma, salivary gland carcinoma, lymphoma, breast cancer, cervical cancer, or ovarian cancer.

[0028c] In one aspect, the present disclosure refers to a kit comprising according to compound as disclosed herein, or a salt or solvate or stereoisomer thereof, wherein optionally the kit further comprises instructions for use in the treatment of cancer.

[0029] Additional examples, features, and advantages of the disclosure will be apparent from the following detailed description and through practice of the disclosure.

CLAIMS

What is claimed is:

1. A compound of the formula:

(i) formula (II):



(II)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

T is a targeting moiety;

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit;

or

(ii) formula (IIa):



(IIa)

or a salt or solvate or stereoisomer thereof;

wherein:

p is 1 to 20;

D is a drug moiety;

T is a targeting moiety;

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit.

2. The compound of formula (IIa) of claim 1, wherein p is 1 to 4.

3. The compound of claim 1 or 2, wherein L^1 is:

(a) a bond; or

(b) a second self-immolative linker or a cyclization self-elimination linker,

wherein optionally

(i) L^1 is an aminobenzyloxycarbonyl linker;

(ii) L^1 is selected from the group consisting of



,



, and



; or

(iii) L^1 is selected from the group consisting of



,



, and



.

4. The compound of any one of claims 1 to 3, wherein L^2 is:

(a) a bond; or

(b) a second self-immolative linker,

wherein optionally

(i) L^2 is an aminobenzyloxycarbonyl linker; or

(ii) L^2 is selected from



,



, and



5. The compound of any one of claims 1 to 4, wherein L^3 is:

(a) a peptide linker of 1 to 10 amino acid residues, wherein optionally L^3 is a peptide linker of 2 to 4 amino acid residues; or

(b) a peptide linker comprising at least one lysine or arginine residue; or

(c) a peptide linker comprising an amino acid residue selected from lysine, D-lysine, citrulline, arginine, proline, histidine, ornithine and glutamine; and/or

a peptide linker comprising an amino acid residue selected from valine, isoleucine, phenylalanine, methionine, asparagine, proline, alanine, leucine, tryptophan, and tyrosine; or

(d) a dipeptide unit selected from valine-citrulline, proline-lysine, methionine-D-lysine, asparagine-D-lysine, isoleucine-proline, phenylalanine- lysine, and valine-lysine, wherein optionally L^3 is valine-citrulline.

6. The compound of any one of claims 1 to 5, wherein L^4 is:

(a) a bond; or

(b) a spacer, wherein optionally

(i) the spacer is polyalkylene glycol, alkylene, alkenylene, alkynylene, or polyamine;

(ii) L^4 is L^{4a}-C(O), L^{4a}-C(O)-NH, L^{4a}-$S(O)_2$, or L^{4a}-$S(O)_2$-NH, wherein each L^{4a} is independently polyalkylene glycol, alkylene, alkenylene, alkynylene, or polyamine;

(iii) L^4 is L^{4a}-C(O), wherein L^{4a} is polyalkylene glycol, alkylene, alkenylene, alkynylene, or polyamine;

(iv) L^4 is L^{4a}-C(O), wherein L^{4a} is a polyalkylene glycol;

(v) L^4 is L^{4a}-C(O), wherein L^{4a} is a polyethylene glycol;

(vi) the spacer is of the formula -CH_2-(CH_2-O-CH_2)$_m$-CH_2-C(O)-, wherein m is an integer from 0 to 30; or

(vii) L^4 is L^{4a}-C(O), wherein L^{4a} is alkylene.

7. The compound of any of claims 1 to 6, wherein A is selected from:

(i) the group consisting of



,



,



,



,



,



,



, and



;

wherein each Q^2 is NH or O, and each q is independently an integer from 1 to 10;

(ii) the group consisting of


and

;

wherein each Q^2 is independently NH or O and each q is independently an integer from 1 to 10, wherein optionally q is 2, 3, 4, or 5; or

(iii) the group consisting of


,


,


,


,


, and


;

wherein each Q^2 is independently NH or O.

8. The compound of any one of claims 1 to 7, wherein T is an antibody;

and wherein optionally T is:

(i) an antibody comprising a heavy chain variable region comprising three CDRs from SEQ ID NO: 1 and a light chain variable region comprising three CDRs from SEQ ID NO: 2;

(ii) an antibody comprising a heavy chain variable region comprising three CDRs from SEQ ID NO: 3 and a light chain variable region comprising three CDRs from SEQ ID NO: 4;

(iii) an antibody comprising a heavy chain variable region comprising amino acids 1-118 of SEQ ID NO: 1 and a light chain variable region comprising amino acids 1-113 of SEQ ID NO: 2;

(iv) an antibody comprising a heavy chain variable region comprising amino acids 1-119 of SEQ ID NO: 3 and a light chain variable region comprising amino acids 1-108 of SEQ ID NO: 4;

(v) an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:1 and a light chain amino acid sequence of SEQ ID NO:2; or

(vi) an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:3 and a light chain amino acid sequence of SEQ ID NO:4.

9. The compound of claim 8, wherein one or more amino acid residues of the heavy chain and/or the light chain is replaced with a cysteine residue;

and optionally

(i) wherein one or more amino acid residues of the heavy chain is replaced with a cysteine residue;

(ii) wherein one or more amino acid residues of the Fc region of the antibody is replaced with a cysteine residue; or

(iii) wherein the one or more amino acid residues of the heavy chain of the antibody at position 157, 169 and/or 442 using EU numbering is replaced with a cysteine residue.

10. The compound of claim 8 or 9, wherein D is linked to T via a cysteine residue through the  moiety.

11. The compound of any one of claims 1 to 10, wherein D is an amino-containing drug moiety, wherein the drug is connected to L^1 through the amino group;

and wherein optionally

(i) D is duocarmycin, dolastatin, tubulysin, doxorubicin (DOX), paclitaxel, or mitomycin C (MMC), or an amino derivative thereof;

(ii) D is selected from the group consisting of



and


;

or (iii) D is:



.

12. The compound of any one of claims 1-11, wherein -A-L^4-L^3-L^2- is



,



,



.



, or



.

13. The compound of any one of claims 1-12, wherein the



moiety is:



,



, or



14. A compound of claim 1, having the formula (III), (IV) or (V):



(III),



(IV), or



(V),

or a salt or solvate or stereoisomer thereof; wherein T is:

(a) an antibody comprising a heavy chain variable region comprising three CDRs from SEQ ID NO: 1 and a light chain variable region comprising three CDRs from SEQ ID NO: 2;

(b) an antibody comprising a heavy chain variable region comprising three CDRs from SEQ ID NO: 3 and a light chain variable region comprising three CDRs from SEQ ID NO: 4;

(c) an antibody comprising a heavy chain variable region comprising amino acids 1-118 of SEQ ID NO: 1 and a light chain variable region comprising amino acids 1-113 of SEQ ID NO: 2;

(d) an antibody comprising a heavy chain variable region comprising amino acids 1-119 of SEQ ID NO: 3 and a light chain variable region comprising amino acids 1-108 of SEQ ID NO: 4;

(e) an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:1 and a light chain amino acid sequence of SEQ ID NO:2; or

(f) an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:3 and a light chain amino acid sequence of SEQ ID NO:4;

or having the formula (IIIa), (IVa) or (Va):



(IIIa),



(IVa), or



(Va),

or a salt or solvate or stereoisomer thereof; wherein p is 1 to 4 and T is:

(a) an antibody comprising a heavy chain variable region comprising three CDRs from SEQ ID NO: 1 and a light chain variable region comprising three CDRs from SEQ ID NO: 2;

(b) an antibody comprising a heavy chain variable region comprising three CDRs from SEQ ID NO: 3 and a light chain variable region comprising three CDRs from SEQ ID NO: 4;

(c) an antibody comprising a heavy chain variable region comprising amino acids 1-118 of SEQ ID NO: 1 and a light chain variable region comprising amino acids 1-113 of SEQ ID NO: 2;

(d) an antibody comprising a heavy chain variable region comprising amino acids 1-119 of SEQ ID NO: 3 and a light chain variable region comprising amino acids 1-108 of SEQ ID NO: 4; (e) an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:1 and a light chain amino acid sequence of SEQ ID NO:2, or

(f) an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:3 and a light chain amino acid sequence of SEQ ID NO:4.

15. A process for making a compound of the formula:

(i) formula (II):



(II)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

T is an antibody;

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit;

comprising reacting an antibody with Compound Z:



(Compound Z),

or a salt or solvate or stereoisomer thereof;

or

(ii) formula (IIa):



(IIa)

or a salt or solvate or stereoisomer thereof;

wherein:

p is 1 to 20;

D is a drug moiety;

T is an antibody;

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit;

comprising reacting an antibody with Compound Z:



(Compound Z),

or a salt or solvate or stereoisomer thereof, optionally wherein the antibody comprises one or more sulfhydryl groups.

16. A compound, or a salt or solvate or stereoisomer thereof, wherein the compound is prepared by a process according to claim 15, wherein the antibody comprises one or more sulfhydryl groups.

17. A pharmaceutical composition comprising the compound of any one of claims 1 to 14 and 16, or a salt or solvate or stereoisomer thereof, and a pharmaceutically acceptable carrier.

18. A compound according to any one of claims 1 to 14 and 16, or a salt or solvate or stereoisomer thereof, for use in a method of killing a cell, the method comprising administering to the cell an amount of said compound sufficient to kill the cell;

wherein optionally the cell is a cancer cell;

and wherein optionally the cancer cell is a gastric cancer cell, pancreatic cancer cell, colorectal cancer cell, lung cancer cell, esophageal cancer cell, gallbladder cancer cell, head and neck cancer cell, liver cancer cell, endometrial carcinoma cell, salivary gland carcinoma cell, lymphoma cell, breast cancer cell, cervical cancer cell, or ovarian cancer cell.

19. A compound according to any one of claims 1 to 14 and 16, or a salt or solvate or stereoisomer thereof, for use in the treatment of cancer;

wherein optionally the cancer is gastric cancer, pancreatic cancer, colorectal cancer, lung cancer, esophageal cancer, gallbladder cancer, head and neck cancer, liver cancer, endometrial carcinoma, salivary gland carcinoma, lymphoma, breast cancer, cervical cancer, or ovarian cancer.

20. A kit comprising according to compound of any one of claims 1 to 14 and 16, or a salt or solvate or stereoisomer thereof, wherein optionally the kit further comprises instructions for use in the treatment of cancer.

21. A method of preparing a compound which is: (i) Compound X:



(Compound X)

or a salt or solvate or stereoisomer thereof;

wherein:

L^2 is a bond or a second self-immolative linker;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

comprising reacting Compound W: A-L^4-L^3-L^2; and Compound I:  ;

(ii) Compound Z:



(Compound Z)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

comprising:

reacting Compound X:  and p-nitrophenyl chloroformate to form Compound Y:  ; and

reacting Compound Y with a compound comprising L^1-D;

(iii) Compound X^1:

 (Compound X^1)

or a salt or solvate or stereoisomer thereof;

wherein:

L^2 is a bond or a second self-immolative linker;

L^3 is a peptide linker; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

comprising: reacting Compound W^1: L^3-L^2; and Compound I:  .

(iv) Compound Y^1:



(Compound Y^1)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

comprising: reacting Compound X^1:  ; and a compound comprising L^1-D;

or (v) Compound Z:



(Compound Z)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;**

A is an acyl unit; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

comprising: reacting Compound Y^1:  , and a compound comprising A-L^4.

22. A compound which is:

(i) a compound of formula:



(Compound X)

or a salt or solvate or stereoisomer thereof;

wherein:

L^2 is a bond or a second self-immolative linker;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

(ii) a compound of formula:



(Compound Z)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker;

L^4 is a bond or a spacer**;** and

A is an acyl unit; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

(iii) a compound of formula:



(Compound X^1)

or a salt or solvate or stereoisomer thereof;

wherein:

L^2 is a bond or a second self-immolative linker;

L^3 is a peptide linker; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

(iv) a compound of formula:



(Compound Y^1)

or a salt or solvate or stereoisomer thereof;

wherein:

D is a drug moiety;

L^1 is a bond, a second self-immolative linker, or a cyclization self-elimination linker;

L^2 is a bond or a second self-immolative linker;

wherein if L^1 is a second self-immolative linker or a cyclization self-elimination linker, then L^2 is a bond;

wherein if L^2 is a second self-immolative linker, then L^1 is a bond;

L^3 is a peptide linker; and

R^1 is hydrogen, unsubstituted or substituted C_{1-3} alkyl, or unsubstituted or substituted heterocyclyl;

or

(v) a compound of Formula (XII)



(XII)

or a salt or solvate or stereoisomer thereof; wherein R is NO_2 or NH_2.

23. Use of a compound according to any one of claims 1 to 14 and 16, or a salt or solvate or stereoisomer thereof, in the manufacture of a medicament for treating cancer;

wherein optionally the cancer is gastric cancer, pancreatic cancer, colorectal cancer, lung cancer, esophageal cancer, gallbladder cancer, head and neck cancer, liver cancer, endometrial carcinoma, salivary gland carcinoma, lymphoma, breast cancer, cervical cancer, or ovarian cancer.